{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(6)"],"submitter":["Yang H"],"pubmed_abstract":["The non-germinal center B-cell like (non-GCB) subtype of diffuse large B-cell lymphoma (DLBCL) has poor clinical outcomes. Bruton tyrosine kinase (BTK) inhibitors have established therapeutic activity in B-cell malignancies, with modest activity in DLBCL. Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in patients with relapsed or refractory (R/R) non-GCB DLBCL. The BGB-3111-207 study (NCT03145064) was a multicenter single-arm phase 2 study. Patients received twice-daily oral zanubrutinib, 160 mg, until disease progression or unacceptable toxicity. The primary end point was the overall response rate (ORR). Secondary end points included progression-free survival (PFS) and duration of response (DOR). Overall survival (OS) was an exploratory end point. Forty-one patients wer"],"journal":["Blood advances"],"pagination":["1629-1636"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8941452"],"repository":["biostudies-literature"],"pubmed_title":["Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma."],"pmcid":["PMC8941452"],"pubmed_authors":["Yang H","Li C","Huang J","Zhang H","Guo W","Novotny W","Zhao W","Zou D","Xiang B","Liu Y","Li Y","Lv F","Tan Z","Guo H","Liu A","Fu L","Song Y"],"additional_accession":[]},"is_claimable":false,"name":"Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.","description":"The non-germinal center B-cell like (non-GCB) subtype of diffuse large B-cell lymphoma (DLBCL) has poor clinical outcomes. Bruton tyrosine kinase (BTK) inhibitors have established therapeutic activity in B-cell malignancies, with modest activity in DLBCL. Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in patients with relapsed or refractory (R/R) non-GCB DLBCL. The BGB-3111-207 study (NCT03145064) was a multicenter single-arm phase 2 study. Patients received twice-daily oral zanubrutinib, 160 mg, until disease progression or unacceptable toxicity. The primary end point was the overall response rate (ORR). Secondary end points included progression-free survival (PFS) and duration of response (DOR). Overall survival (OS) was an exploratory end point. Forty-one patients wer","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2026-05-10T01:38:13.961Z","creation":"2025-02-19T01:11:53.492Z"},"accession":"S-EPMC8941452","cross_references":{"pubmed":["34638136"],"doi":["10.1182/bloodadvances.2020003698"]}}